MAPT and Alzheimer disease: While it is impossible to directly compare the performance of Lumipulse plasma p-tau181 to these assays, a recent framework to validate plasma tau biomarkers for AD diagnosis has been developed [36, 37] and proper head-to-head comparisons between the various assays are currently underway.